Influence of Medicinal Cannabis (Bedrocan) on the pharmacokinetics of irinotecan and docetaxel in cancer patients (METC 2003-171 Erasmus MC).

Completed

• Conditions: Cancer <br />see also inclusion criteria: <br />1. Histological or cytological confirmed diagnosis of any form of (metastatic) cancer; <br />1.1 which is refractory to conventional treatment; or<br />1.2 for which no other (effective) treatment options are available.

• Registration Number: NL-OMON24424
• Lead Sponsor: Erasmus MC- Daniel den Hoed Kliniek, afdeling Interne Oncologie.

Brief Summary

1. Oncologist. 2007 Mar;12(3):291-300. <br> <br><br> 2. de Jong FA, Engels FK, Sparreboom A, Loos WJ, de Bruijn P, Friberg LE, Mathôt RAA, Verweij J, Mathijssen RHJ. Influence of medicinal Cannabis on the pharmacokinetics of Docetaxel and Irinotecan. Proc Amer Assoc Cancer Res 2005; 46:[Abstract 3985].<br> <br><br> 3. de Jong FA, Engels FK, Verweij J, Mathijssen RHJ. Influence of medicinal cannabis on the pharmacokinetics of the anticancer drugs irinotecan and docetaxel. 3rd Conference of the International Association for Cannabis as Medicine, 2005.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

1. Histological or cytological confirmed diagnosis of any form of (metastatic) cancer;

1.1 which is refractory to conventional treatment; or

Exclusion Criteria

1. Pregnant or lactating patients; patients with reproductive potential must use a reliable method of contraception (excluding oral contraceptives), if required.

2. Symptomatic CNS metastases.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Irinotecan and metabolite pharmacokinetics, course 1 and 2<br>Docetaxel pharmacokinetics, course 1 and 2.

Secondary Outcome Measures

Name	Time	Method
Hematological toxicity course 1 and 2.